Part 2 of our pick of the most exciting AIM arrivals in 2021
AIM’s status as the market of choice for early-stage life science companies came to the fore in 2021, with the top performing newcomer in the year coming from the life sciences arena and plenty of other interesting newcomers from this area as well.
In pre-Covid days, AIM’s life sciences companies struggled to attract much attention from UK investors with the share prices of many languishing. Covid-19 appears to have brought a dramatic change in investors’ attitude towards the sector, initially driven by diagnostic groups developing Covid tests and subsequently by companies with a host of different life sciences offerings. AIM’s top performing newcomer in 2021 came from the life sciences sector and we sense that 2022 will continue to see life sciences attract plenty of interest. Not all of these small, early-stage companies will go onto successfully commercialise their products and services, but…